Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
58.25
-1.08 (-1.82%)
At close: Feb 19, 2026, 4:00 PM EST
57.53
-0.72 (-1.24%)
After-hours: Feb 19, 2026, 6:39 PM EST
Bio-Techne Revenue
Bio-Techne had revenue of $295.88M in the quarter ending December 31, 2025, a decrease of -0.39%. This brings the company's revenue in the last twelve months to $1.22B, up 1.64% year-over-year. In the fiscal year ending June 30, 2025, Bio-Techne had annual revenue of $1.22B with 5.23% growth.
Revenue (ttm)
$1.22B
Revenue Growth
+1.64%
P/S Ratio
7.50
Revenue / Employee
$392,122
Employees
3,100
Market Cap
9.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.22B | 60.58M | 5.23% |
| Jun 30, 2024 | 1.16B | 22.36M | 1.97% |
| Jun 30, 2023 | 1.14B | 31.10M | 2.81% |
| Jun 30, 2022 | 1.11B | 174.57M | 18.75% |
| Jun 30, 2021 | 931.03M | 192.34M | 26.04% |
| Jun 30, 2020 | 738.69M | 24.69M | 3.46% |
| Jun 30, 2019 | 714.01M | 71.01M | 11.04% |
| Jun 30, 2018 | 642.99M | 79.99M | 14.21% |
| Jun 30, 2017 | 563.00M | 63.98M | 12.82% |
| Jun 30, 2016 | 499.02M | 46.78M | 10.34% |
| Jun 30, 2015 | 452.25M | 94.48M | 26.41% |
| Jun 30, 2014 | 357.76M | 47.19M | 15.19% |
| Jun 30, 2013 | 310.58M | -3.99M | -1.27% |
| Jun 30, 2012 | 314.56M | 24.60M | 8.48% |
| Jun 30, 2011 | 289.96M | 20.92M | 7.77% |
| Jun 30, 2010 | 269.05M | 5.09M | 1.93% |
| Jun 30, 2009 | 263.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| Halozyme Therapeutics | 1.40B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 561.26M |
| Krystal Biotech | 389.13M |
| Cytokinetics | 87.21M |
| ImmunityBio | 82.56M |
| Praxis Precision Medicines | 7.46M |
TECH News
- 3 days ago - Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories - PRNewsWire
- 8 days ago - Bio-Techne Announces Changes to its Leadership Team - PRNewsWire
- 15 days ago - Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Biotech firm Bio-Techne beats quarterly estimates on strength in key unit - Reuters
- 15 days ago - Bio-Techne Declares Dividend - PRNewsWire
- 15 days ago - Bio-Techne Releases Second Quarter Fiscal 2026 Results - PRNewsWire
- 17 days ago - Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative - PRNewsWire
- 22 days ago - Madison Mid Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha